Table 2

Change in serum sTRAIL levels and association with survival.

Response Status

Survival

(month)

Serum sTRAIL Level (ng/ml)


Alive (n = 7)

20,6 ± 0,5

1,38 ± 0,10

Dead (n = 9)

9,4 ± 0,9

0,92 ± 0,05


Statistical analysis (unpaired

t-test)

p < 0,05 (p = 0,0001)

p < 0,05 (p = 0,0002)


Metastatic colon cancer patients who were treated with bevacizumab, and had increased levels of serum sTRAIL after treatment, had an extended median survival time up to 20.6 months. In contrast, median survival was 9.4 months for patients with decreased or unchanged sTRAIL after the bevacizumab therapy

Bisgin et al. BMC Cancer 2012 12:58   doi:10.1186/1471-2407-12-58

Open Data